Your session is about to expire
← Back to Search
BAY 2416964 + Pembrolizumab for Cancer
Study Summary
This trial is looking for a new way to treat cancer by using a drug to block a protein called Aryl Hydrocarbon Receptor (AhR). The study drug, BAY 2416964, is a small molecule which blocks the AhR allowing the body to use its immune response against the cancer cells. Researchers think that BAY 2416964 given together with a cancer treatment called pembrolizumab may help shrink tumors in people with cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Dose escalation of BAY2416964
- Group 2: Dose expansion of BAY2416964 in tumor type specific cohort
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what disease states is BAY2416964 typically used to offer relief?
"BAY2416964 is a common medication for cancer treatment, and it has been found to be effective in the management of unresectable melanoma, microsatellite instability high (MSI-H), as well as disease progression after chemotherapy."
How many venues are managing this experiment?
"The 6 participating medical centres are located in Austin, Detroit and Nashville among others. It is advisable to choose the clinic closest to you when signing up for this trial so as to reduce travel burden."
Are recruiting efforts for this research endeavor ongoing?
"According to the information provided by clinicaltrials.gov, this research is currently looking for participants. The initial posting took place on August 30th 2021 and the most recent update was made November 14th 2022."
Has any other research explored BAY2416964?
"Currently, there are 961 clinical trials underway researching BAY2416964. Of those studies, 122 have progressed to Phase 3. Although the majority of experiments related to this drug are conducted in Houston, Texas - across 35 743 different sites - investigations for BAY2416964 can be found all over the world."
Does BAY2416964 pose any health risks to humans?
"The safety of BAY2416964 is rated at 1 due to the limited data available for this Phase 1 trial, which does not yet provide sufficient information about efficacy and security."
What is the enrollment count for this trial at present?
"Affirmative, according to clinicaltrials.gov the medical trial that commenced on August 30th 2021 is actively enrolling. 78 participants are sought from 6 sites for this research study."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger